| Oct 24 |
Lyell Immunopharma to acquire ImmPACT Bio
|
| Oct 24 |
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
|
| Oct 24 |
Lyell, in search of a turnaround, to buy cell therapy startup ImmPact
|
| Oct 4 |
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
|
| Sep 24 |
Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day
|
| Aug 28 |
Lyell Immunopharma Announces Participation in September Investor Conferences
|
| Aug 24 |
Recent uptick might appease Lyell Immunopharma, Inc. (NASDAQ:LYEL) institutional owners after losing 32% over the past year
|
| Aug 8 |
Lyell Immunopharma reports Q2 results
|
| Aug 7 |
Lyell Immunopharma: Q2 Earnings Snapshot
|
| Aug 7 |
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024
|
